

Haematologica
HAEMATOL/2018/208454
Version 3

How close are we to incorporating measurable residual disease into
clinical practice for acute myeloid leukemia?

Nicholas J. Short and Farhad Ravandi

Disclosures: Funding source: Supported by the MD Anderson Cancer Center Support Grant CA016672. Disclosure of Conflicts of Interest: The authors have no relevant conflicts of interest.

Contributions: N.S. and F.R. wrote the manuscript and approve of the final version.